Nucleus Biologics Wins Fierce Innovation Award for 2021

14 Dec 2021
Fierce_Life_Sciences_Award 2021-100

NB-AIR™ Artificial Intelligence Research platform recognized with prestigious Pharma and Biotech innovation award

Nucleus Biologics is pleased to announce that its NB-AIR™ Artificial Intelligence Research platform was selected as the winner of this year’s Fierce Innovation award for Data Analytics and Business Intelligence by Fierce Life Sciences [1]. This is a prestigious award from the publisher of Fierce Biotech and Fierce Pharma; the Fierce Innovation Awards identify and showcase outstanding innovations with the greatest potential to impact the biotech and pharma industries.

The Data Analytics/Business Intelligence category recognizes greatness in business intelligence using data science, data management, and data analytics with the highest potential to better serve the industry. A fiercely competitive field judged by a panel of leading experts drawn from across the Biotech and Pharma industry.

“We are honored to have been chosen for this award by Fierce, one of the leading biotech news organizations,” said David Sheehan, President and CEO of Nucleus Biologics. “Our excitement is what this product means for cell therapy developers. This tool uses AI to harness the power of all the published articles and allow scientists to quickly create cell media that yields a more potent, cost effective, and defined therapy solution that can treat patients in need.”

Shortfalls in Cell Culture Media are Holding Back Therapeutic Development

Driven by the dramatic growth in cell, gene, and regenerative medicine, the pace of change and discovery in cell culture in recent years has been truly staggering. The ability to support and nurture cells outside of the human body has become a critical factor in the development of these powerful new therapeutics, but the sheer volume of publications makes it impossible for researchers to stay abreast of all the latest developments and discoveries. Indeed, most of the existing proprietary off-the-shelf formulations available from suppliers are now 5-10 years old, way behind the latest scientific research on high-performance cell culture, and a serious impediment to the development of novel therapeutics.

Using Artificial Intelligence to Design Cell Media for Therapeutic Applications

Wins Fierce Innovation Award

The Nucleus Biologics’ Artificial Intelligence Research (NB-AIR) platform which won the award utilizes artificial intelligence and machine learning to design optimized cell culture media for use in therapeutic products. A cutting-edge cell-culture media configuration tool capable of parsing all the published data to select a media formulation specific to an individual cell type and therapeutic application. To put that in perspective, there are over 490,000 publications on T-cells, and over 65,000 on mesenchymal stem cells alone, way beyond the capability of any human reviewer.

NB-AIR enables researchers to specify their cell type, along with their Critical Quality Attributes (CQA), the characteristics that they wish to enhance, or the problems they wish to address in their cells. Using a simple, intuitive, cloud-based interface NB-AIR leads a researcher through the process of selecting the attributes of their desired media. The AI-based platform then parses thousands of publications to provide media recommendations that the researchers can order in trial quantities, compressing the whole process of custom media design down from weeks to just hours. This now makes the time frame for selecting and approving the highest quality custom media comparable with that for off-the-shelf formulations that are years behind the latest research. Unique amongst media suppliers, Nucleus Biologics also supplies the full ingredient and formulation list to its customers, a critical benefit that accelerates regulatory approval.

It is this innovative solution to a critical problem that has been recognized by the award from Fierce Life Sciences. Smoothing the path from research, to development, to clinical practice for new therapeutics. You can read more about the groundbreaking NB-AIR platform on the Nucleus Biologics website or click here to sign up for a free trial of NB-AIR.


  1. Fierce Life Sciences Innovation Awards 2021 Winner:

Share this article

Brad N. Taylor, Ph.D.
Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry before joining Nucleus Biologics. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.